Champions Oncology, Inc.

As of July 31, 2026, Champions Oncology, Inc. carries a market capitalization of 65.42M, placing it among publicly traded companies globally. Its enterprise value stands at 71.25M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Champions Oncology, Inc.'s next confirmed earnings release is scheduled for December 15, 2026.

As of July 31, 2026, Champions Oncology, Inc. has 13.92M shares outstanding.

These figures are as of July 31, 2026. The price-to-sales ratio is 1.24, and the price-to-book ratio stands at 19.38.

As of July 31, 2026, Champions Oncology, Inc. trades at an EV/EBITDA multiple of 264.20 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 71.25M versus a market cap of 65.42M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Champions Oncology, Inc. maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended July 31, 2026, Champions Oncology, Inc. posted a negative return on equity (ROE) of -29.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.36, reflecting losses generated across the asset base. The company generates approximately 246,394.47 in revenue per employee across its workforce of 213.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended July 31, 2026, Champions Oncology, Inc. recorded 210,729.60 in income tax expense. The company reported a pretax loss of -773,542.40 and -930,505.60 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Champions Oncology, Inc.'s stock has declined approximately 24.56% over the past 52 weeks. The 50-day moving average sits at 4.36, while the 200-day moving average is 5.02.

Over the twelve months ended July 31, 2026, Champions Oncology, Inc. generated 52.61M in revenue and converted that into -930,505.60 in net income, yielding earnings per share of -0.07. EBITDA reached 269,699.20, while operating income came in at -808,230.40.

As of July 31, 2026, Champions Oncology, Inc. holds 3.78M in cash and equivalents against 9.12M in total debt, resulting in a net debt position of -3.78M. Total book value stands at 3.38M, with working capital of 488,233.60 providing operational flexibility.

Champions Oncology, Inc. produced -4.83M in operating cash flow over the twelve months ended July 31, 2026. After subtracting -496,905.60 in capital expenditures, free cash flow totaled -5.32M - equivalent to -0.38 per share.

Over the twelve months ended July 31, 2026, Champions Oncology, Inc. posted a gross margin of 49.82, reflecting its pricing power and cost economics. The operating margin of -1.54 and net profit margin of -1.77 provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -8.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.19, meaning Champions Oncology, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Champions Oncology, Inc.'s most recent stock split took place on August 12, 2015 with a 12:1 split ratio.

As of July 31, 2026, Champions Oncology, Inc. has an Altman Z-Score of -0.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.